Navigation Links
Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
Date:1/22/2008

Speed in Reaching First Clinical Milestone Validates Approach

SAN FRANCISCO, January 22 /PRNewswire/ -- Synosia Therapeutics today announced the successful completion of its first clinical trial, a proof-of-concept study that evaluated new therapeutic options for SYN-111 (rufinamide), a sodium channel blocker. Rufinamide was discovered and developed by Novartis and is currently marketed by Eisai in Europe as a drug to treat a form of epilepsy. This first trial was completed in less than seven months from design to final dosing and less than a year after the rights to rufinamide in mood disorders were obtained from Novartis in an exclusive licensing agreement.

The placebo-controlled, double-blind, three-dose study measured drug effect and pattern of response using quantitative electroencephalography (EEG) in healthy volunteers, who all received each dose plus placebo. After each dose, the subject's brain waves were evaluated over the course of 24 hours, noting quantitative change in each wave and the pattern of the change as an indication of rufinamide activity. The study was conducted in France.

"The data from this study lend support to observations in animal behaviour models and further justify investigation of the effect of rufinamide for mood disorders," said Stephen Bandak, Synosia's Chief Medical Officer. "The study has also helped us select a dose for our Phase 2 trial in general anxiety disorder scheduled to start in the United States later this year."

Rights to SYN111 were obtained by Synosia from Novartis in 2007 in an exclusive worldwide (outside of Japan) licensing agreement to develop and commercialise rufinamide for the treatment of anxiety and other mood disorders. It is estimated that over 62 million people in the United States and the five major European pharmaceutical markets suffer from a form of anxiety. Of those, over nine million suffer from general anxiety disorder.(1, 2)

"Our development approach of
'/>"/>

SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 This is a ... and China Isopropanol (IPA) industry. The report provides ... applications and industry chain structure. Global market analysis ... a focus on history, developments, trends and competitive ... international and Chinese situation is also offered. , ...
(Date:9/23/2014)... New York , September 23, 2014 /PRNewswire/ ... a leading provider of  Closed System Transfer     ... new exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation. ... bodies in Taiwan , ... approval as the company continues to expand globally, ...
(Date:9/23/2014)... Greenville, SC (PRWEB) September 23, 2014 ... ) my third book on healthcare offers a three ... a 21st century healthcare delivery system that would go ... each state’s responsibility regarding the delivery of healthcare.” , ... patient safety has failed to provide discernable progress throughout ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
Breaking Biology Technology:(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer and ... has received FDA clearance for the,marketing of the ATS 3f(R) ... an improved valve holder accessory device. , ... While the ATS 3f Aortic ...
... Cytopia,s (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th ... be presented by Dr Thomas Bumm of Oregon Health and Sciences ... model of myeloproliferative disorders. , , Full ... CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induc e ...
... http://www.yourwaytransport.com ), a premium global courier that provides,customized ... biotechnology and medical/healthcare industries, today,announced that it is ... The,expansion includes a new, larger facility, enhanced web ... The company has relocated ...
Cached Biology Technology:ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3Yourway Transport Expands 2
(Date:9/23/2014)... gotten a lot greener thanks to a novel technique ... uses solar energy to accelerate tailings pond reclamation efforts ... a light source to treat oil sands process affected ... El-Din and James Bolton have found that using the ... just as efficiently but at a much lower cost. ...
(Date:9/23/2014)... A multidisciplinary team at the University of Wisconsin-Madison and ... more affordable way to screen for neural toxins, helping ... National Institutes of Health (NIH) announced today that the ... support to continue the promising work as part of ... will receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... soils store four times more carbon than the ... can have a big effect on atmospheric greenhouse ... Nature Climate Change concludes that climate ... or affect soil carbon storage, despite increases in ... U.S. Forest Service Research Ecologist Dr. Christian Giardina, ...
Breaking Biology News(10 mins):Solar energy-driven process could revolutionize oil sands tailings reclamation 2UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3Study helps assess impact of temperature on belowground soil decomposition 2
... Zoo-based Wildlife Conservation Society (WCS) warn that efforts to ... beyond must focus on better management practices on farms ... Mongolian agencies on the ground in Mongolia's Kovsgol province, ... the virus. , "We're working with our Mongolian and ...
... anyone with respiratory problems, air pollution can significantly impair ... satellites and stations on the ground to develop a ... quality forecasts. , Understanding how tropospheric or near-surface-level ozone ... region to region and continent to continent is an ...
... may have a surprisingly close-to-home answer, according to one University ... is important in obtaining clues as to where else in ... be like, said George E. Fox, a UH professor of ... research grant from NASA's Exobiology Program that seeks to understand ...
Cached Biology News:WCS says avian flu prevention should focus on farms, markets 2Sensor web simulation investigates technique to improve prediction of pollution across the globe 2Sensor web simulation investigates technique to improve prediction of pollution across the globe 3Evolution of life on Earth may hold key to finding life in outer space 2Evolution of life on Earth may hold key to finding life in outer space 3
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Biology Products: